嵌合抗原受体修饰T细胞治疗急性髓细胞白血病的研究进展

Research progress of chimeric antigen receptor modified T cells in treatment of acute myeloid leukemia

急性髓细胞白血病（AML）是一种常见的血液系统恶性肿瘤，临床治疗以传统化疗方案为主，该病复发率高，且预后差。近年，应用嵌合抗原受体修饰T细胞（CAR—T）治疗血液系统恶性肿瘤的研究，尤其是采用CD19CAR-T治疗B细胞恶性肿瘤，取得了快速发展。多项研究结果表明，CAR—T在AMI。治疗中，也展现出良好的发展前景。笔者拟就嵌合抗原受体（CAR）的结构、CAR-T治疗AML的研究进展，以及CAR-T免疫疗法的局限性进行综述。

Acute myeloid leukemia （AML） is a common malignant tumor in blood system. It is mainly treated with traditional chemotherapy. The recurrence rate of AML is high and its prognosis is poor. In recent years, applications of chimeric antigen receptor modified T ceils （CAR-T） in treatment of hematological malignancies, especially in CD19 CAR-T treatment of B ceils malignant tumor, has achieved rapid development. A number of studies have shown that CAR-T treatment also performed an important role in AML. This review will discuss structure of chimeric antigen receptor （CAR）, advances of CAR-T in treatment of AML, and limitations of CAR T immunotherapy.